Page 38 - Read Online
P. 38

Shephard et al.                                                                                                                                                                     Role of exosomes in prostate cancer

           identified on EV from a variety of different cancer cell   Sustained growth of the tumor mass often requires
           types and are summarized in Table 1. Further studies   new blood vessels to provide rapidly proliferating
           are required to  ascertain whether these factors are   tumor  cells  with  an  adequate  supply  of  metabolites
           present on prostate cancer EV.                     and oxygen. Under hypoxic conditions the cellular
                                                              secretome becomes altered and a proportion of these
           DELIVERY OF PRO-ANGIOGENIC RNAS BY                 changes may reside within the exosome fraction.
           EXOSOMES                                           Exosomes derived from solid tumors, which have
                                                              been cultured in hypoxic conditions, become enriched
           Whilst direct evidence of RNA delivery by prostate   with hypoxia-regulated mRNAs and proteins such as
           cancer EV is currently lacking, EV from several cancer   Caveolin 1, IL-8, matrix metalloproteinase (MMP) and
           types are known to be enriched with mRNA transcripts   PDGF, and are capable of promoting angiogenesis [31] .
           related to pro-angiogenic  function that can then be   Similarly, under hypoxic conditions, the secretion of
           translated by recipient cells [26,27] . Similar studies have   exosomes from breast cancer [32]  or leukemic cells [33]
           shown an enhanced proliferative impact on endothelial   demonstrate elevated levels of exosomal miR-210,
           cells [28,29]  and enhanced tubule formation within 3D cell   with the capacity to enhance HUVEC tube formation
           cultures . The transfer of exosomal miRNA, such as   compared  to  exosomes  from  normoxic  conditions.
                  [28]
           miRNA-92a and  miR-17-92, may  also play a  role in   Although EV from hypoxic prostate cancer cells are yet
           this process  and miR-17-92 may play a role in this   to be investigated, based on this evidence, it is highly
                      [30]
           process . Furthermore, transmittance of the miR-   likely that the cargo of prostate cancer exosomes is
                  [30]
           17-92 cluster from EV to endothelial  cells has been   also  influenced  by  hypoxic  conditions.  The  impact
           shown to attenuate endothelial expression of integrin   of hypoxia-derived vesicles on angiogenesis and
           α  resulting in enhanced endothelial cell migration and   subsequent development of prostatic tumors remains
            v
           tube formation . Numerous studies highlight a role of   unknown.
                        [30]
           cancer  exosomes  in delivery  of RNAs to endothelial
           cells, thereby promoting  angiogenesis,  and it is   INDIRECT EXOSOME-MEDIATED
           therefore likely that prostate cancer exosomes share   ANGIOGENESIS
           this functionality.
                                                              In addition to direct modulation of angiogenesis within
           HYPOXIC TUMOR-DERIVED EXOSOMES                     the tumor microenvironment, exosomes  have the
           ENHANCE ANGIOGENESIS                               potential to regulate angiogenesis indirectly through
                                                              interactions  with various  non-endothelial  cell types.
           As a tumor grows diffusion distances from the existing   Prostate cancer exosomes, expressing transforming
           vascular supply increase, resulting in hypoxia.    growth factor beta (TGFβ),  can  activate  fibroblasts
           Table 1: EV-associated pro-angiogenic proteins
           Protein                      Pro-angiogenic function            Cancer cell of EV origin  Reference
           Angiogenin      Translocates to the nucleus of recipient cells and enhances RNA   Multiple myeloma  [131]
                           transcription, stimulating expression of pro-angiogenic proteins
           EGFR            Induces VEGF expression in recipient cells through Akt signaling  Lung, glioma  [132,133]
           FAK               Interactions between FAK, IGF-1R and Src result in various   Prostate    [21]
                            downstream signaling events and modulation of angiogenesis
           FGF2             Promotes proliferation and differentiation of endothelial cells  Multiple myeloma  [131]
           IGF-1R            Interactions between FAK, IGF-1R and Src result in various   Prostate    [21]
                            downstream signaling events and modulation of angiogenesis
           MMP-2, MMP-9          Degradation of extracellular matrix components   Ovarian            [134]
           Src             Activation of FAK, and subsequent formation of focal adhesions   Prostate, myeloid leukemia  [21,135]
                                         between endothelial cells
           Tspan8           Induces uPA, VEGFR and vWF in recipient endothelial cells  Pancreatic   [134,135]
           uPA               Activation of plasminogen leading to vascular remodeling  Prostate       [24]
           VEGF            Rearranges the cytoskeleton through the FAK/paxillin pathway,   Multiple myeloma, ovarian  [131,134]
                          induces capillary formation via RhoA/ROCK signaling and controls
                                     vascular permeability through PLCγ
           A selected overview of pro-angiogenic factors previously identified on EV. Association of pro-angiogenic proteins with EV has been
           demonstrated in multiple cancers, but the precise involvement of some such proteins in prostate cancer remains unclear. EV: extracellular
           vesicles; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth factor; Akt: protein kinase B (serine/threonine specific
           protein kinase); FAK: focal adhesion kinase; IGF-1R: insulin-like growth factor 1 receptor; Src: proto-oncogene tyrosine-protein kinase
           Src; FGF2: fibroblast growth factor 2; MMP: matrix metalloproteinase; Tspan8: tetraspanin-8; uPA: urokinase-type plasminogen activator;
           VEGFR: vascular endothelial growth factor receptor; vWF: von willebrand factor; RhoA: Ras homolg gene family, member A; ROCK: Rho-
           associated, coiled-coil containing protein kinase; PLCγ: phospholipase C gamma
            290                                                                Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017
   33   34   35   36   37   38   39   40   41   42   43